The activation of the platelet GP IIb/IIIa receptor is the final and common pathway in platelet aggregation. By blocking this receptor, platelet aggregation can be inhibited independently of the stimulus prompted the targeting of this receptor. Several years ago, three drugs have been approved for coronary artery indications. Since that time, there is increasing evidence that GP IIb/IIIa receptor blockade might have also an important role in peripheral arterial intervention. This article summarizes the action and differences of GP Ilb/IIIa receptor inhibitors and its possible indication in peripheral arteries.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-005-0266-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects.
Eur J Anaesthesiol
January 2025
From the Department of Cardiovascular Sciences, KU Leuven (LLWV, SR, RVdE), and the Department of Anesthesiology, University Hospital of the KU Leuven, Leuven, Belgium (LLWV, SR, RVdE).
Background: Cardiac surgery involving cardiopulmonary bypass (CPB) is associated with the risk of acquired coagulopathy, including dysregulated fibrinolysis, which can result in life-threatening bleeding complications. Aprotinin, an antifibrinolytic agent, has been recommended for the prevention of these complications. Its effectiveness has been attributed to its ability to nonspecifically inhibit various serine proteases involved in the coagulation and fibrinolysis cascade.
View Article and Find Full Text PDFSafety and efficacy of cangrelor in endovascular thrombectomy compared with glycoprotein IIb/IIIa Inhibitors.
J Neurointerv Surg
October 2024
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Article Synopsis
- Cangrelor, an intravenous P2Y12-receptor inhibitor, is compared to traditional antithrombotic medications like eptifibatide in patients undergoing endovascular thrombectomies (EVTs), with previous data being insufficient for direct comparison.
- A study reviewed clinical data from 1010 EVT patients who received either cangrelor or eptifibatide to assess safety and efficacy, focusing on outcomes like hemorrhagic conversion and functional status using scales like the mRS and NIHSS.
- Results showed that cangrelor was linked to a lower risk of hemorrhagic conversion and better functional outcomes at discharge and follow-up, indicating its potential benefits over GPIs in this specific medical context
Platelet Function, Platelet Size and Content of Reticulated Platelets: Interactions in Patients Receiving Dual Antiplatelet Therapy.
Cells
October 2024
Chazov National Medical Research Center of Cardiology, Russian Ministry of Health, 15a, Academician Chazov Str., Moscow 121552, Russia.
Increased platelet activity is a risk factor of thrombotic events in cardiovascular patients. We studied the relationship between platelet function, platelet size, and the content of reticulated platelets (RP) in patients with coronary heart disease (CHD, n = 55) and acute coronary syndrome (ACS, n = 95) receiving acetylsalicylic acid + clopidogrel or ticagrelor, respectively. The control group consisted of patients with risk factors for CHD, but with no CHD/ACS and free of antiplatelet drugs (n = 66).
View Article and Find Full Text PDFLong-Term Survival Outcomes in Locally Advanced Breast Cancer after Mastectomy with or without Breast Reconstruction.
Oncology
October 2024
Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction: There is ongoing debate about the safety of breast reconstruction for patients with locally advanced breast cancer (LABC) who have undergone total mastectomy (TM). More and more LABC patients are undergoing breast reconstruction after TM, but its long-term survival outcomes remain unclear. This study aimed to compare the survival outcomes of LABC patients who underwent breast reconstruction after TM with those who did not, based on a large sample.
View Article and Find Full Text PDFDownstream cangrelor versus upstream ticagrelor in patients with ST-segment elevation myocardial infarction: A propensity score-matched analysis.
Int J Cardiol
January 2025
Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy. Electronic address:
Background: Pretreatment with a P2Y inhibitor may be considered in patients with ST-segment elevation myocardial infarction (STEMI) referred to percutaneous coronary intervention (PCI). Intravenous cangrelor is an alternative in this setting, where oral absorption can be hindered. The aim of this study was to compare cangrelor administered after coronary angiography (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!